CorMedix Inc. — Director's Dealing 2012

Dec 7, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2012-12-05

Reporting Person: MILBY RANDY (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-05	Stock Option (right to buy)	$0.68	A	100000	Acquired	2022-12-05	Common Stock, $0.001 par value per share (100000)	Indirect

Footnotes

F1: These options vest as follows: fifty-percent (50%) on the date of issuance of the CE Mark approval in Europe for the Company's Neutrolin(R) product candidate, if the CE Mark approval is obtained on or before March 31, 2013, and fifty-percent (50%) on December 31, 2013.

F2: The reporting person was granted options through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).